Hookipa Pharma Inc [HOOK] stock prices are up 16.91% to $0.80 at the moment. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The HOOK shares have gain 21.64% over the last week, with a monthly amount glided 26.98%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 29, January 2024, HOOKIPA Pharma Provides Update on Business Priorities and Oncology Partnership Programs. In a post published today on Yahoo Finance, HOOKIPA to prioritize clinical development of HB-200 for the treatment of HPV16+ head and neck cancers and Gilead-partnered programs in infectious disease.
From an analyst’s perspective:
Hookipa Pharma Inc [NASDAQ: HOOK] stock has seen the most recent analyst activity on December 02, 2022, when BofA Securities downgraded its rating to a Underperform but kept the price target unchanged to $0.50 for it. Previously, BofA Securities downgraded its rating to Underperform on December 02, 2022. On November 12, 2021, downgrade downgraded it’s rating to Equal-Weight but maintained its price target of $6 on the stock. Morgan Stanley started tracking the stock assigning a Overweight rating and suggested a price target of $19 on April 08, 2021. Truist initiated its recommendation with a Buy and recommended $21 as its price target on November 03, 2020. JMP Securities started tracking with a Mkt Outperform rating for this stock on October 26, 2020, and assigned it a price target of $19.
The stock price of Hookipa Pharma Inc [HOOK] has been fluctuating between $0.41 and $2.05 over the past year. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Hookipa Pharma Inc [NASDAQ: HOOK] shares were valued at $0.80 at the most recent close of the market. An investor can expect a potential return of 275.0% based on the average HOOK price forecast.
Analyzing the HOOK fundamentals
The Hookipa Pharma Inc [NASDAQ:HOOK] reported sales of 20.55M for trailing twelve months, representing a surge of 207.94%. Gross Profit Margin for this corporation currently stands at 0.85% with Operating Profit Margin at -3.91%, Pretax Profit Margin comes in at -3.36%, and Net Profit Margin reading is -3.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.42, Equity is -0.71 and Total Capital is -0.65. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.04.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.7087 points at the first support level, and at 0.6173 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.8707, and for the 2nd resistance point, it is at 0.9413.
Hookipa Pharma Inc [HOOK] reported earnings per share of -$0.17 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.21/share, meaning a difference of $0.04 and a surprise factor of 19.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.22 per share as compared to estimates of -$0.21 per share, a difference of -$0.01 representing a surprise of -4.80%.
Ratios To Look Out For
It’s worth pointing out that Hookipa Pharma Inc [NASDAQ:HOOK]’s Current Ratio is 3.44. As well, the Quick Ratio is 3.44, while the Cash Ratio is 2.65. Considering the valuation of this stock, the price to sales ratio is 3.27, the price to book ratio is 0.71.
Transactions by insiders
Recent insider trading involved Kandera Reinhard, Chief Financial Officer, that happened on Aug 21 when 7000.0 shares were purchased. Chief Financial Officer, Kandera Reinhard completed a deal on Aug 16 to buy 8000.0 shares. Meanwhile, Chief Executive Officer Aldag Jorn bought 5000.0 shares on Jul 11.
